Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 15/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.48 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30661004 | 1.00 | IKBKB (0.60) | IKBKBPARP1ALDH1A1KDM4EGAA | |
| Hydrochloric Acid SCHEMBL31161184 | 0.98 | IKBKB (0.58) | IKBKBPARP1ALDH1A1KDM4EGAA | |
| SCHEMBL28276351 | 0.98 | IKBKB (0.58) | IKBKBPARP1ALDH1A1KDM4EGAA | |
| Butyric Acid SCHEMBL29114521 | 0.86 | PARP1 (0.49) | IKBKBPARP1ALDH1A1KDM4EGAA | |
| SCHEMBL902623 | 0.84 | ALDH1A1 (0.66) | IKBKBALDH1A1KDM4EHDAC1HDAC6 | |
| SCHEMBL27450141 | 0.84 | PARP1 (0.64) | IKBKBPARP1ALDH1A1KDM4EGAA | |
| SCHEMBL27449612 | 0.83 | PARP1 (0.51) | IKBKBPARP1ALDH1A1KDM4EGAA | |
| SCHEMBL27418513 | 0.83 | PARP1 (0.51) | IKBKBPARP1ALDH1A1KDM4EGAA | |
| SCHEMBL27449144 | 0.83 | PARP1 (0.51) | PARP1ALDH1A1KDM4EGAAPARP2 | |
| SCHEMBL27544144 | 0.83 | PARP1 (0.51) | PARP1ALDH1A1KDM4EGAAPARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 254 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414526-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | Pharmacia Corporation (US) | 2004-05-06 | — | — | EP | claimed |
| CN-1116285-C | Bis(acridinecarboxamide) and Bis(phenazinecarboxamide) as antitumour agents | XENOVA LTD (GB) | 2003-07-30 | — | — | CN | claimed |
| WO-2002085459-A2 | ANTIANGIOGENIC COMBINATION THERAPY FOR THE TREATMENT OF CANCER | PHARMACIA CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | claimed |
| CN-1240431-A | Process for preparation of N-[2-(dimethylamino) ethyl] acridine-4-carboxamide | XENOVA LTD (GB) | 2000-01-05 | — | — | CN | claimed |
| US-20240239730-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-07-18 | — | — | US | disclosed |
| EP-4389765-A2 | METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER | University of Southern California (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20240197891-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4374929-A2 | METHODS AND DEVICES FOR USING ISOPERILLYL ALCOHOL | University of Southern California (US) | 2024-05-29 | — | — | EP | disclosed |
| US-20240156764-A1 | INHIBITION OF URACIL DNA GLYCOSYLASE IN THE OPEN CONFORMATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | disclosed |
| US-11970436-B2 | Pharmaceutical compositions comprising monoterpenes | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2024-04-30 | — | — | US | disclosed |
| US-11952415-B2 | Scaffold proteins | AVACTA LIFE SCIENCES LIMITED (GB) | 2024-04-09 | — | — | US | disclosed |
| EP-0934278-B1 | BIS(ACRIDINECARBOXAMIDE) AND BIS(PHENAZINECARBOXAMIDE) AS ANTITUMOUR AGENTS | XENOVA LTD (GB) | 2002-09-04 | — | — | EP | disclosed |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | PHARMACIA CORPORATION | 2002-08-01 | — | — | US | disclosed |
| CN-1240430-A | Bis(acridinecarboxamide) and Bis(phenazinecarboxamide) as antitumour agents | XENOVA LTD (GB) | 2000-01-05 | — | — | CN | disclosed |
| CN-1240431-A | Process for preparation of N-[2-(dimethylamino) ethyl] acridine-4-carboxamide | XENOVA LTD (GB) | 2000-01-05 | — | — | CN | disclosed |
| EP-0934277-A1 | PROCESS FOR THE PREPARATION OF N- 2-(DIMETHYLAMINO)ETHYL]ACRIDINE-4-CARBOXAMIDE | XENOVA LIMITED (GB) | 1999-08-11 | — | — | EP | disclosed |
| WO-1998045272-A1 | TOPOISOMERASE INHIBITORS | LATROBE UNIVERSITY (AU) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998017649-A1 | PROCESS FOR THE PREPARATION OF N-[2-(DIMETHYLAMINO)ETHYL]ACRIDINE-4-CARBOXAMIDE | XENOVA LIMITED (GB) | 1998-04-30 | — | — | WO | disclosed |
| WO-1996000715-A1 | NEW [2-(3,4-DIMETHOXY-PHENYL)-ETHYL]-(2-PHENOXY-ETHYL)-AMINES, A PROCESS FOR PREPARING THE SAME AND THEIR USE AS MEDICAMENTS | ARZNEIMITTELWERK DRESDEN GMGH (DE) | 1996-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239730-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING MONOTERPENES | SQLE, DHPS, GGPS1 | IKBKB 758/4885PARP1 221/4885ALDH1A1 793/4885 |
| US-20240197891-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES | PLIN3, PLIN5, PLIN1 | IKBKB 1405/4885PARP1 231/4885ALDH1A1 102/4885 |
| US-11952415-B2 | Scaffold proteins | TPD52L2, Q6ZSR9, G3BP2 | IKBKB 4011/4885PARP1 3433/4885ALDH1A1 4787/4885 |
| US-11970436-B2 | Pharmaceutical compositions comprising monoterpenes | SQLE, DHPS, GGPS1 | IKBKB 758/4885PARP1 221/4885ALDH1A1 793/4885 |
| US-20020103141-A1 | Antiangiogenic combination therapy for the treatment of cancer | TOP2A, TOP2B, TOP1 | IKBKB 281/4885PARP1 61/4885ALDH1A1 1074/4885 |
| US-20240156764-A1 | INHIBITION OF URACIL DNA GLYCOSYLASE IN THE OPEN CONFORMATION | UNG, OGG1, MPG | IKBKB 421/4885PARP1 86/4885ALDH1A1 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.